Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for StenoparibEuropean Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementBoston (October 10, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on October 9, 2024, it received a formal notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”). The notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq’s Listing Rule 5550(a)(2) (the “Bid Price Rule”). Nasdaq noted that since September 11, 2024, Allarity’s stock has maintained a closing bid price of $1.00 or more for 20 consecutive trading days, thereby meeting the requirements for regaining compliance with the Bid Price Rule.
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)Boston (September 11, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company is taking a decisive step toward regaining compliance with Nasdaq’s listing requirements, as outlined by the Nasdaq Hearings Panel during a meeting on August 15, 2024.
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized SharesBoston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the upcoming annual meeting of stockholders scheduled on July 26, 2024.
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining ComplianceBoston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it received notice from the NASDAQ Stock Market (“NASDAQ”) that it was granted a hearing before a Nasdaq Hearings Panel (the “Panel”).
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementBoston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it has received formal written notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”) that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”).
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerBoston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer. The patients enrolled in the trial had been pre-screened by Allarity’s unique Drug Response predictor (DRP®) companion diagnostic (CDx) in order to treat only patients with the highest likelihood of deriving clinical benefit.
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementBoston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on April 27, 2024, it received formal notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”). This notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq’s Listing Rule 5550(a)(2) (the “Bid Price Rule”). Nasdaq noted that since April 9, 2024, Allarity’s stock has maintained a closing bid price above $1.00 per share for more than ten consecutive trading days, thereby meeting the requirements for regaining compliance.
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1).
Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitBoston (April 4, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 9:30 a.m. Eastern Time on April 9, 2024. The Company’s common stock will begin trading on a split-adjusted basis when the market opens on April 9, 2024. This strategic move aims to regain compliance with the Nasdaq’s minimum bid price requirement, alongside achieving other operational benefits. The CUSIP number for the Company’s common stock following the Reverse Stock Split will be 016744401.
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal extension until April 24, 2024 to regain compliance under Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”) or any of the alternative requirements in Listing Rule 5550(b).
Allarity Therapeutics to Present at Biomarkers 2024Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive AdvisorBoston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (
NASDAQALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced a transition in its leadership. Effective immediately, James G. Cullem is no longer President and CEO. The Company also announced that Thomas H. Jensen, co-founder and member of the Board of Directors of Allarity Therapeutics, has been appointed as Interim Chief Executive Officer. The Company has also engaged Jeremy R. Graff, Ph.D., as an Executive Advisor. Dr. Graff will work closely with Mr. Jensen and the Board to provide consulting and advisory services on Allarity’s research and development programs in the field of small molecule inhibitors and their use in the treatment of cancer.
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to unselected patients
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public OfferingBOSTON, MA (July 6, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the pricing of its “reasonable best efforts” public offering of 2,444,445 shares of common stock (or common stock equivalents in lieu thereof) and common warrants to purchase up to 2,444,445 shares of common stock at an effective combined price of $4.50 per share and common warrant for aggregate gross proceeds of approximately $11 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $4.50 per share, will be exercisable immediately and will expire five years from the initial exercise date.
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public OfferingAllarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
Allarity Therapeutics Announces Reverse Stock Split of Common StockCommon Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing RequirementsCambridge, MA U.S.A. (October 11, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the second quarter ended June 30, 2022.
